Fundraising Fox
/Companies
Sign in

Biodesix

NASDAQ: BDSX

Boulder, US · Delaware corporation · 1 known investors

Find your way into Biodesix

Biodesix is a diagnostic solutions company that develops and provides advanced diagnostic tests, with a focus on lung disease and cancer, to support clinical decisions and personalized patient care. It also offers custom diagnostic development services to biopharmaceutical, life sciences, and research institutions.

BiotechDigital HealthHealthtech

Founders & leadership

DB
David BrunelExecutive
FR
Frank RonchettiExecutive
RHRobin Harper Cowie
Robin Harper CowieChief Financial Officer
KOKieran O'Kane
Kieran O'KaneChief Commercial Officer

Board

JS
Jack SchulerBoard director
JP
John PatienceBoard director
MS
Matthew StrobeckBoard director
MM
Mark MillerBoard director
RC
Robert CawthornBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$140M disclosed across 14 of 16 rounds · 1900–2026

▶$16MraisedOct 2020 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jean FranchiDirector
  • Hany MassaranyDirector
  • Charles WattsDirector
  • Bobbi CoffinExecutive Officer
  • Gary Pestano, Ph.D.Executive Officer
  • Jim PurvisExecutive Officer
  • Linda Traylor, Ph.D.Executive Officer
  • Paul Beresford, Ph.D.Executive Officer
  • Scott HuttonExecutive Officer, Director
  • Robin CowieExecutive Officer
  • Matthew StrobeckDirector
  • Mark MillerDirector
  • Jack SchulerDirector
  • John PatienceDirector
  • Robert CawthornDirector
  • David BrunelDirector
  • Robert GeorgantasExecutive Officer
Offering amount
$31M
Amount sold
$16M
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.9MraisedAug 2019 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Linda Traylor, Ph.D.Executive Officer
  • Jim PurvisExecutive Officer
  • Gary Pestano, Ph.D.Executive Officer
  • Bobbi CoffinExecutive Officer
  • Charles WattsDirector
  • Robert GeorgantasExecutive Officer
  • David BrunelExecutive Officer, Director
  • Robert CawthornDirector
  • John PatienceDirector
  • Jack SchulerDirector
  • Mark MillerDirector
  • Matthew StrobeckDirector
  • Robin CowieExecutive Officer
  • Scott HuttonExecutive Officer
  • Paul Beresford, Ph.D.Executive Officer
Offering amount
$10M
Amount sold
$4.9M
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.5MraisedOct 2018 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matt StaufferExecutive Officer
  • Mark MillerDirector
  • Matthew StrobeckDirector
  • Robin CowieExecutive Officer
  • Paul Beresford, Ph.D.Executive Officer
  • Bobbi CoffinExecutive Officer
  • Gary Pestano, Ph.D.Executive Officer
  • Jim PurvisExecutive Officer
  • John PatienceDirector
  • Robert CawthornDirector
  • David BrunelExecutive Officer, Director
  • Linda Traylor, Ph.D.Executive Officer
  • Scott HuttonExecutive Officer
  • Heinrich Roder, D.Phil.Executive Officer
  • Jack SchulerDirector
Offering amount
$27.5M
Amount sold
$17.5M
First sale
Oct 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jack SchulerDirector
  • Mark MillerDirector
  • Paul Beresford, Ph.D.Executive Officer
  • Bobbi CoffinExecutive Officer
  • Matthew StrobeckDirector
  • Robin CowieExecutive Officer
  • John PatienceDirector
  • Linda Traylor, Ph.D.Executive Officer
  • David BrunelExecutive Officer, Director
  • Scott HuttonExecutive Officer
  • Jim PurvisExecutive Officer
  • Robert CawthornDirector
  • Heinrich Roder, D.PhilExecutive Officer
  • Gary Pestano, Ph.D.Executive Officer
Offering amount
$8M
Amount sold
$8M
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.3MraisedMay 2018 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jack SchulerDirector
  • Paul Beresford, Ph.D.Executive Officer
  • Scott HuttonExecutive Officer
  • Linda Traylor, Ph.D.Executive Officer
  • John PatienceDirector
  • Heinrich Roder, D.Phil.Executive Officer
  • Gary Pestano, Ph.D.Executive Officer
  • Jim PurvisExecutive Officer
  • Bobbi CoffinExecutive Officer
  • David BrunelExecutive Officer, Director
  • Robin CowieExecutive Officer
  • Mark MillerDirector
  • Robert CawthornDirector
  • Matthew StrobeckDirector
Offering amount
$10.3M
Amount sold
$5.3M
First sale
Apr 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedMar 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Heinrich Roder, D.Phil.Executive Officer
  • Bobbi CoffinExecutive Officer
  • Jack SchulerDirector
  • Paul Beresford, Ph.D.Executive Officer
  • John PatienceDirector
  • David BrunelExecutive Officer, Director
  • Gary Pestano, Ph.D.Executive Officer
  • Jim PurvisExecutive Officer
  • Robert CawthornDirector
  • Linda Traylor, Ph.D.Executive Officer
  • Matthew StrobeckDirector
  • Scott HuttonExecutive Officer
  • Mark MillerDirector
  • Robin CowieExecutive Officer
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Feb 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.2MraisedApr 2017 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robin CowieExecutive Officer
  • Mark MillerDirector
  • Heinrich Roder, D.Phil.Executive Officer
  • Paul Beresford, Ph.D.Executive Officer
  • Gary Pestano, Ph.D.Executive Officer
  • Wendy BlosserExecutive Officer
  • Jim PurvisExecutive Officer
  • Robert CawthornDirector
  • Jack SchulerDirector
  • Bobbi CoffinExecutive Officer
  • John PatienceDirector
  • Linda Traylor, Ph.D.Executive Officer
  • Liz FliegelmanExecutive Officer
  • Matthew StrobeckDirector
  • David BrunelExecutive Officer, Director
Offering amount
$25.3M
Amount sold
$13.2M
First sale
Apr 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.1MraisedNov 2016 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John PatienceDirector
  • Jack SchulerDirector
  • David BrunelExecutive Officer, Director
  • Matthew StrobeckDirector
  • Robert CawthornDirector
  • Mark MillerDirector
  • Robin CowieExecutive Officer
Offering amount
$15.7M
Amount sold
$5.1M
First sale
Nov 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$400.6Mvaluation at IPOOct 2020 · $18.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Biodesix do?
Biodesix is a diagnostic solutions company that develops and provides advanced diagnostic tests, with a focus on lung disease and cancer, to support clinical decisions and personalized patient care. It also offers custom diagnostic development services to biopharmaceutical, life sciences, and research institutions.
Who are Biodesix's investors?
Biodesix's investors include Colorado BioScience Association.
How much funding has Biodesix raised?
Biodesix has disclosed $140M raised across 14 of its 16 known rounds.
Where is Biodesix headquartered?
Biodesix is headquartered in Boulder, US.